Preclinical drug development for childhood cancer

被引：7

作者：

Moreno, Lucas ^{[1
,2
]}

Chesler, Louis ^{[1
,2
]}

Hargrave, Darren ^{[1
]}

Eccles, Suzanne A. ^{[3
]}

Pearson, Andrew D. J. ^{[1
,4
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Children & Young Peoples Unit, Sutton SM2 5PT, Surrey, England

[2] Inst Canc Res, Sect Paediat Oncol, Neuroblastoma Drug Dev Team, Surrey, England

[3] Canc Res UK Ctr Canc Therapeut, Inst Canc Res, Surrey, England

[4] Inst Canc Res, Sect Paediat Oncol, Surrey, England

来源：

EXPERT OPINION ON DRUG DISCOVERY | 2011年 / 6卷 / 01期

关键词：

animal models; cancer; cell lines; children; drug development; targeted therapy; ENGINEERED MOUSE MODELS; BRAIN-STEM GLIOMA; HEDGEHOG PATHWAY INHIBITOR; PHASE-I TRIALS; N-MYC; MALIGNANT PROGRESSION; TESTING PROGRAM; IGF-1; RECEPTOR; MEDULLOBLASTOMA; CHILDREN;

D O I：

10.1517/17460441.2011.537652

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Importance of the field: More effective drugs are needed to treat poor prognosis paediatric malignancies. Development of anticancer agents for childhood cancers faces several unique challenges compared with their adult counterparts. Areas covered in this review: We demonstrate how recent advances in preclinical drug development may overcome these difficulties and challenges. We explain the role of academia, regulators and industry in this field, address issues with preclinical models and illustrate several examples of biology-driven drug development in childhood cancers. What the reader will gain: Increased knowledge about preclinical drug development in paediatric oncology including different preclinical models, established preclinical research networks, and relationships among academia, industry and regulators, as illustrated by several examples of targeted agents in childhood solid malignancies. Take home message: It is anticipated that emerging advanced preclinical models and testing platforms will provide a more efficient, biologically-driven rationale to support the use of targeted therapies in several malignancies such as neuroblastoma, medulloblastoma or high grade glioma which account for the majority of deaths related to childhood cancer.

引用

页码：49 / 64

页数：16

共 50 条

[21] Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum [J].

Dubois, Steven G. ;

Moreno, Lucas ;

Anderson, John ;

Asgharzadeh, Shahab ;

Bagatell, Ro ;

Beck-Popovic, Maja ;

Belle, Jen ;

Berlanga, Pablo ;

Bird, Nick J. ;

Chesler, Louis ;

Durbin, Adam ;

Eggert, Angelika ;

Eilers, Martin ;

Federico, Sara M. ;

Fischer, Matthias ;

Gatz, Susanne A. ;

George, Rani E. ;

George, Sally ;

Goldsmith, Kelly C. ;

Gray, Juliet ;

Heczey, Andras ;

Irwin, Meredith S. ;

Knox, Leona ;

Lode, Holger N. ;

Ludwinski, Donna ;

Macy, Margaret E. ;

Majzner, Robbie G. ;

Maris, John M. ;

Modak, Shakeel ;

Molenaar, Jan J. ;

Morgenstern, Daniel A. ;

Mosse, Yael P. ;

Owens, Cormac ;

Reynolds, C. Patrick ;

Rossig, Claudia ;

Schleiermacher, Gudrun ;

Scott, Liz ;

Sondel, Paul M. ;

Speleman, Frank ;

van Noesel, Max ;

Westermann, Frank ;

Wienke, Judith ;

Wolpaw, Adam J. ;

Park, Julie R. ;

Pearson, Andrew D. J. .

PEDIATRIC BLOOD & CANCER, 2025,

[22] Longitudinal development of fatigue after treatment for childhood cancer: a national cohort study [J].

Irestorm, Elin ;

van Gorp, Marloes ;

Twisk, Jos ;

Nijhof, Sanne ;

de Bont, Judith ;

Grootenhuis, Martha ;

van Litsenburg, Raphaele .

ACTA ONCOLOGICA, 2023, 62 (10) :1309-1321

[23] Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations [J].

Barnett, Shelby ;

Holden, Victoria ;

Campbell-Hewson, Quentin ;

Veal, Gareth J. .

FRONTIERS IN ONCOLOGY, 2022, 11

[24] Cancer Chemoprevention: Preclinical In Vivo Alternate Dosing Strategies to Reduce Drug Toxicities [J].

Mohammed, Altaf ;

Fox, Jennifer T. ;

Miller, Mark Steven .

TOXICOLOGICAL SCIENCES, 2019, 170 (02) :251-259

[25] Molecular Imaging in Cancer Drug Development [J].

Waaijer, Stijn J. H. ;

Kok, Iris C. ;

Eisses, Bertha ;

Schroder, Carolina P. ;

Jalving, Mathilde ;

Brouwers, Adrienne H. ;

Lub-de Hooge, Marjolijn N. ;

de Vries, Elisabeth G. E. .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) :726-732

[26] Proteomics and metabolomics in cancer drug development [J].

D'Alessandro, Angelo ;

Zolla, Lello .

EXPERT REVIEW OF PROTEOMICS, 2013, 10 (05) :473-488

[27] Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates [J].

Amrita V. Kamath ;

Suhasini Iyer .

Pharmaceutical Research, 2015, 32 :3470-3479

[28] A multistep validation process of biomarkers for preclinical drug development [J].

W M Freeman ;

G V Bixler ;

R M Brucklacher ;

C-M Lin ;

K M Patel ;

H D VanGuilder ;

K F LaNoue ;

S R Kimball ;

A J Barber ;

D A Antonetti ;

T W Gardner ;

S K Bronson .

The Pharmacogenomics Journal, 2010, 10 :385-395

[29] Onchocerciasis drug development: from preclinical models to humans [J].

Adela Ngwewondo ;

Ivan Scandale ;

Sabine Specht .

Parasitology Research, 2021, 120 :3939-3964

[30] Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates [J].

Kamath, Amrita V. ;

Iyer, Suhasini .

PHARMACEUTICAL RESEARCH, 2015, 32 (11) :3470-3479

← 1 2 3 4 5 →